NextCure, Inc. (NXTC)

In November 2025, NextCure closed a $21.5 million private placement of common stock to extend its cash runway into the first half of 2027 and support its ADC programs. The company provided a business update and reported its third-quarter 2025 financial results in November 2025. In October 2025, NextCure and Simcere Zaiming expanded their Phase 1 trial of SIM0505 into the United States. NextCure reported a widening Q2 loss in August 2025. In July 2025, the company announced encouraging preclinical data for NC605, leading to a stock surge. NextCure secured global rights to SIM0505 and partnered with Simcere Zaiming for its development in June 2025. In May 2025, NextCure provided a business update and reported its first-quarter 2025 financial results. In March 2025, the company provided a business update and reported full-year 2024 financial results. NextCure's stock touched a 52-week low in December 2024, and the FDA accepted an IND application for LNCB74 in December 2024.

Demand seasonality is not applicable to NextCure, Inc., as it is a clinical-stage biopharmaceutical company focused on research and development rather than the commercial sale of products. The company's revenue is not generated from product sales but rather from collaborations, grants, and financing activities.

NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunomedicines for cancer and immune-related diseases, operating within the Biotechnology and Pharmaceutical Preparations industry. The company uses its Therapeutic Discovery Engine (TDE™) to identify and optimize new targets in the immune response pathway. Its product candidates include LNCB74, an ADC targeting B7-H4; SIM0505, an ADC targeting CDH6; NC410, a fusion protein of LAIR-2; NC525, a novel LAIR-1 antibody; NC181, a humanized antibody targeting ApoE4; NC605, an antibody targeting Siglec-15; NX-1607, an oral small molecule inhibitor targeting the CD200 checkpoint; NX-0255, a monoclonal antibody directed against KIR3DL2; and NX-5948, an oral Bruton's tyrosine kinase (BTK) degrader. As a clinical-stage company, NextCure does not have any approved or marketed products.

NextCure, Inc. is headquartered in Beltsville, Maryland, United States, and conducts clinical trials across North America and Europe. It has a strategic partnership with Simcere Zaiming for the development of SIM0505, with Simcere Zaiming retaining Greater China rights and NextCure holding global rights excluding Greater China. U.S. trial enrollment for SIM0505 began in October 2025, following prior dose escalation in China.

NextCure's brand reputation is primarily tied to its scientific advancements, clinical trial progress, and financial stability. Positive news, such as encouraging preclinical data for NC605 and the expansion of clinical trials for SIM0505, along with successful private placements, contribute positively to the company's standing. The company's focus on developing novel immunotherapies for unmet medical needs in cancer also contributes to a perception of innovation and commitment to patient care.

NextCure, Inc. has a significant portion of its shares held by institutional investors, including Sofinnova Investments, Inc., Affinity Asset Advisors, LLC, Pfizer Inc, Vanguard Group Inc, Cable Car Capital LLC, Acadian Asset Management Llc, BlackRock, Inc., Renaissance Technologies Llc, Geode Capital Management, Llc, and Sio Capital Management, LLC. Sofinnova Investments, Inc. held the largest shareholding position with over 222,654 shares, representing 9.25% of total outstanding shares as of September 30, 2025. Individual insiders own approximately 1.26% of the company's shares.